The Paracrine Regulation of Mast Cells During Biliary/Cholangiocyte Repair and Damage

胆管/胆管细胞修复和损伤过程中肥大细胞的旁分泌调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): Cholangiopathies (Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC)) are characterized by the proliferation/loss of cholangiocytes, which are the cells that line the biliary epithelium. During cholestasis, biliary hyperplasia/damage is regulated by both autocrine/paracrine mechanisms. For example, during hyperplastic cholangiocyte proliferation bile duct mass increases and proliferating cholangiocytes release numerous factors like histamine presumably to sustain the increased bile duct mass. In ductopenic states, bile duct mass decreases and cholangiocytes are damaged and unable to maintain biliary homeostasis. We have shown that: (i) cholangiocytes express histamine receptors (HRs) and histidine decarboxylase (HDC), the key enzyme regulating histamine synthesis; (ii) cholangiocytes release histamine; and (iii) inhibition of biliry HDC decreases both hyperplastic and neoplastic cholangiocyte growth and vascular endothelial growth factor (VEGF) by autocrine pathways. Besides the autocrine regulation of cholangiocyte proliferation/loss, paracrine regulation of biliary function by neighboring hepatic cells must be considered. It has been demonstrated in patients with PBC and PSC that histamine plasma levels are higher and that there are increased numbers of hepatic mast cells in the proximity of bile ducts. When activated, hepatic mast cells release numerous factors like histamine into the microenvironment, which we propose influence cholangiocyte proliferative/apoptotic responses in cholangiopathies. In our proposal, we present preliminary data supporting the hypothesis that mast cells infiltrate the liver following damage via c-kit/SCF interaction and that mast cells alte the proliferative response of small and large cholangiocytes in models of liver damage or repair by interaction with H1 and H2 HRs and specific microRNAs. Our proposed studies are innovative and will likely provide important, clinically relevant data to add to the understanding f the regulation of biliary disorders and also offer insight into novel treatment strategies.
描述(由申请人提供):胆管病(原发性胆汁性肝硬化(PBC)和原发性硬化性胆管炎(PSC))的特征是胆管细胞的增殖/损失,胆管细胞是胆上皮细胞。在胆汁淤积期间,胆汁增生/损伤是由自分泌/旁分泌机制调节的。例如,在增生性胆管细胞增殖过程中,胆管体积增加,增殖的胆管细胞释放出许多因子,如组胺,可能是为了维持胆管体积的增加。在胆管减少状态下,胆管体积减少,胆管细胞受损,无法维持胆道稳态。研究结果表明:(1)胆管细胞表达组胺受体(HRs)和组氨酸脱羧酶(HDC),组氨酸脱羧酶是调节组胺合成的关键酶;(ii)胆管细胞释放组胺;(iii)抑制胆汁HDC通过自分泌途径降低增生性和肿瘤性胆管细胞的生长和血管内皮生长因子(VEGF)。除了对胆管细胞增殖/损失的自分泌调节外,还必须考虑邻近肝细胞对胆道功能的旁分泌调节。已证实PBC和PSC患者的血浆组胺水平较高,胆管附近的肝肥大细胞数量增加。当被激活时,肝肥大细胞释放许多因子,如组胺到微环境中,我们认为这些因子影响胆管病变中胆管细胞的增殖/凋亡反应。在我们的提案中,我们提供的初步数据支持以下假设:肥大细胞在损伤后通过c-kit/SCF相互作用浸润肝脏,肥大细胞通过与H1和H2 hr和特异性microrna相互作用改变肝损伤或修复模型中大小胆管细胞的增殖反应。我们提出的研究具有创新性,可能会提供重要的临床相关数据,以增加对胆道疾病调节的理解,并为新的治疗策略提供见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Heather L Francis其他文献

Heather L Francis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Heather L Francis', 18)}}的其他基金

Mast Cell Regulation of Alcohol-Induced Liver Damage
肥大细胞对酒精引起的肝损伤的调节
  • 批准号:
    10539568
  • 财政年份:
    2022
  • 资助金额:
    $ 25.3万
  • 项目类别:
Mast Cell Regulation of Alcohol-Induced Liver Damage
肥大细胞对酒精引起的肝损伤的调节
  • 批准号:
    10686244
  • 财政年份:
    2022
  • 资助金额:
    $ 25.3万
  • 项目类别:
BLR&D Research Career Scientist Award
BLR
  • 批准号:
    10618234
  • 财政年份:
    2020
  • 资助金额:
    $ 25.3万
  • 项目类别:
BLR&D Research Career Scientist Award
BLR
  • 批准号:
    10454100
  • 财政年份:
    2020
  • 资助金额:
    $ 25.3万
  • 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
  • 批准号:
    9764884
  • 财政年份:
    2019
  • 资助金额:
    $ 25.3万
  • 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
  • 批准号:
    10410390
  • 财政年份:
    2019
  • 资助金额:
    $ 25.3万
  • 项目类别:
The Paracrine Regulation of Mast Cells During Biliary/Cholangiocyte Repair and Damage
胆管/胆管细胞修复和损伤过程中肥大细胞的旁分泌调节
  • 批准号:
    9923327
  • 财政年份:
    2019
  • 资助金额:
    $ 25.3万
  • 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
  • 批准号:
    9982325
  • 财政年份:
    2019
  • 资助金额:
    $ 25.3万
  • 项目类别:
Mechanisms of mast cell/cholangiocyte regulation of non-alcoholic fatty liver disease progression
肥大细胞/胆管细胞对非酒精性脂肪肝疾病进展的调节机制
  • 批准号:
    10170334
  • 财政年份:
    2019
  • 资助金额:
    $ 25.3万
  • 项目类别:
Mechanisms of synergistic regulation of biliary inflammation and fibrosis
胆道炎症和纤维化的协同调节机制
  • 批准号:
    9206411
  • 财政年份:
    2016
  • 资助金额:
    $ 25.3万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 25.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 25.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 25.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了